What was approved and why it matters
Novocure's Optune Pax is a wearable device that delivers Tumor Treating Fields, alternating electric fields, to the abdomen. It is used alongside gemcitabine and nab-paclitaxel in adults with locally advanced pancreatic cancer and is worn for at least 18 hours a day. It is the first device approved to treat pancreatic cancer.
Frequently asked questions
When was Optune Pax approved?
The FDA granted premarket approval to Optune Pax in February 2026 for adults with locally advanced pancreatic cancer, used with gemcitabine and nab-paclitaxel. It received a CE Mark in June 2026 and Japanese approval in October 2026.
What are Optune Pax's projected sales?
Zaash Labs' base case is about USD 95 million of US net revenue in 2031, within a range of USD 36 million to 185 million, driven mainly by how many eligible patients start and stay on the device and by net payment per month.
What did PANOVA-3 show?
In 571 patients, median overall survival was 16.2 months with Tumor Treating Fields plus chemotherapy against 14.2 months with chemotherapy alone, and pain free survival was 15.2 against 9.1 months.
Figures are company reported or from published sources unless marked as Zaash Labs estimates. Sources are listed in the executive summary and the full report. Market research to support business decisions; not investment advice.